The IMspire 150, a phase III clinical trial carried out by 112 institutes in 20 countries, was the first to demonstrate a potential benefit of the so-called triple therapy in the treatment of patients with metastatic cutaneous melanoma. Rodrigo Perez Pereira, Leader of Care Practices in Skin Tumors of the Oncoclínicas Group and one of the authors of the study, explains that “this treatment involves a double blockade of the MAP kinase pathway, with vemurafenib (BRAF blocker) and cobimetinib (MEK blocker) , which are oral drugs, in combination with atezolizumab, an immune checkpoint inhibitor (anti-PD-L1). In this sense, it is extremely important for opening up another therapeutic possibility for this patient population”.
Another similar work, COMBI-i, did not achieve the primary endpoint when analyzing a triple combination of therapies in patients with advanced melanoma. According to Frederico Arthur P. Nunes, clinical oncologist at Grupo Oncoclínicas Rio de Janeiro and member of the National Melanoma and Sarcoma Committee of Grupo Oncoclínicas, in this study, after a median follow-up of 27.2 months, there was no benefit in progression-free survival with triple treatment compared to the dual therapy arm: “Overall survival was not tested statistically, and medians were not achieved in both arms,” he explains.
Go to our website and read the full article with all the details of these studies.